bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology
bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European patent for opti-ox, a breakthrough technology enabling deterministic forward programming of pluripotent stem cells (PSCs), including iPSCs.
bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces its comprehensive program for Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). This premier event, recognised as the world's largest forum for emerging neurological discoveries, will take place October 5-9, 2024, at Chicago's McCormick Place Convention Center.
bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial Officer
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the appointment of Przemek Obloj as Chief Financial Officer. Mr. Obloj will oversee the company’s financial strategy, including fundraising, and work closely with bit.bio’s Founder and CEO, Mark Kotter, and the executive team to support bit.bio’s continued growth and innovation.
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the launch of ioAstrocytes. This new addition to bit.bio’s ioCells portfolio creates an unparalleled toolkit for disease research that addresses the challenges of data reproducibility and enables accelerated therapeutic development.
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder Mark Kotter. Dr. Südhof, a world-renowned molecular and cellular neuroscientist and professor at Stanford University, will be joined by Dr. Kotter, a stem cell biologist, neurosurgeon at the University of Cambridge, and CEO of bit.bio, to discuss "Programming Human Cells: The Next Frontier of SynBio for Human Health." The fireside chat will explore how the new paradigm of cell programming, combined with our ability to read, write and execute genetic code, opens unprecedented opportunities for improving human health. The discussion will be held during the closing plenary session at SynBioBeta on Thursday, May 9th, from 4-6 pm PT at the San Jose Convention Center in California.
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE:
DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network. The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
bit.bio, the company coding human cells for novel cures, has launched ioMotor Neurons as its 12th ioCells product this year. This takes the total number of products in the ioCells range - human cells for research and drug discovery - to 20 products, including wild type, CRISPR-ready and disease model cells. The launch of ioMotor Neurons also follows the recent opening of bit.bio’s new manufacturing and automation laboratories by the UK’s Minister for Science, Research and Innovation.
Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher
bit.bio, the company coding human cells for novel cures, and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announce a collaboration to build multi-cell models of the human brain using bit.bio’s ioCells™️.
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy
bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025. The company also announced three key additions to its Scientific Advisory Board (SAB).
bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery
bit.bio, the company coding human cells for novel cures, today announces the launch of the first offering from its new product range - ioCRISPR-Ready Cells™. This new range has been designed for scientists looking to generate gene knockouts in physiologically relevant human cells.
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines
bit.bio, a synthetic biology company focused on human cells, has achieved a milestone in the manufacture of human cells. Based on their opti-oxTM 1- based transcription factor reprogramming technology, bit.bio has reached a new level of precision and consistency of their induced pluripotent stem cells (iPSC)-derived cell products.
bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery
bit.bio, the cell coding company today launches its new Custom ioDisease Model Cells offering. This offering allows scientists to commission their disease-relevant mutation of interest in bit.bio's human induced pluripotent stem cell (iPSC)-derived cells powered by opti-ox technology.
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist
Cell coding company bit.bio today announces the addition of its early stage investor Weslie Janeway as a Board member. With her extensive experience on both company and non profit boards, she will bring her innovative and purpose driven mindset to the governance of the company.
bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases
Cell coding company bit.bio today announces three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons.
bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company
Today bit.bio welcomes two new members to its independent Ethics and Sustainability Board to further support the company’s commitment to being a purpose led, ethical organisation. bit.bio is working towards a future in which precision engineered human cells enable biomedical innovation (UN SDG9) and a new generation of cures (UN SDG3).
bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
Cell coding company bit.bio has announced an expansion to its product portfolio - ioGlutamatergic Neurons TDP-43M337V disease model and early access to its ioMicroglia cell product.
bit.bio named Emerging Star at European Mediscience Awards 2022
Last night bit.bio won the Emerging Star prize at the European Mediscience Awards in a ceremony at the Hotel InterContinental in London.
bit.bio Presents Data at ISSCR Demonstrating Their Platform’s Capability to Create Any Human Cell
bit.bio, a synthetic biology company working on developing and providing any human cell type at scale, will present development and characterisation data on glutamatergic neurons, skeletal myocytes, microglia and associated disease models at this year’s International Society for Stem Cell Research Conference (ISSCR) today.
bit.bio Celebrates Double Award Win at Cambridge Science and Technology Awards 2022 Including Biotech of the Year for the Second Time in a Row
Members of the bit.bio were celebrating last week to mark their double win at the Cambridge Independent Science and Technology Awards this month.
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
bit.bio, a synthetic biology company working on developing and providing every human cell type at scale, with the aim of transforming the research and medicine landscape, today launch their ioGlutamatergic Neurons HTT50CAG/WT cells to advance research and accelerate drug discovery for Huntington’s disease. This disease model, one of the first of its kind to be commercially available, accurately reflects the genetics of the disease.
Bit.bio Appoints Accomplished Biotechnology Executive and Drug Developer Kathryn Corzo as Chief Operating Officer
Cell coding company bit.bio today announces the key appointment of Kathryn Corzo as Chief Operating Officer. She started in the role on 1 November 2021.
bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
Human cell coding company bit.bio today announces the first close of their Series B financing of $103 million.
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will provide important guidance as bit.bio scales their proprietary synthetic biology cell programming technology platform, creating products and solutions based on human cells that can transform healthcare from basic research and drug discovery to next generation cell based therapies.
